TG-1042 is under clinical development by Transgene and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect TG-1042’s likelihood of approval (LoA) and phase transition for Cutaneous B-Cell Lymphoma took place on 09 Oct 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their TG-1042 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

TG-1042 overview

TG-1042 (ASN-002) is under development for the treatment of basal cell carcinoma, relapsing primary cutaneous B-cell lymphomas and nodular basal cell carcinoma, cutaneous head and neck squamous cell carcinoma, basal cell carcinoma in patients with gorlin syndrome and recurrent ovarian cancer. It is administered by intratumor injection. TG-1042 is a recombinant adenovirus encoding the human immunoregulatory cytokine interferon gamma (IFNgamma). It was also under development for the treatment of metastatic melanoma, cutaneous B-cell lymphoma and cutaneous T cell lymphoma.

Transgene overview

Transgene, a subsidiary of Institut Merieux SA, operates as a biotechnology company. The company offers discovery and development of immunotherapies in the areas of cancer and infectious diseases. It provides products such as therapeutic vaccines and oncolytic viruses. Transgene develops targeted immunotherapies utilizing a broad range of viral vectors. The company also concentrates on discovery of a novel approach to improve digestion of DNA impurities in the manufacturing of viral vectors. It operates through collaborations with numerous reference clinical centers, university hospitals and medical centers. It has operations in France, the US and China. Transgene is headquartered in Illkirch-Graffenstaden, France.

Quick View TG-1042 LOA Data

Report Segments
  • Innovator
Drug Name
  • TG-1042
Administration Pathway
  • Intratumor
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Transgene
  • Originator: Transgene
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.